Skip to content
lifestyle.nextmentors.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
PulseSight Therapeutics S.A.S
PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy
October 7, 2026
EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 treatment for dry AMD/Geographic Atrophy (GA)
September 16, 2026
Positive Results from PulseSight’s Phase I Clinical Trial of PST-611 in Dry AMD/Geographic Atrophy Presented at ARVO 2026
May 11, 2026
Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
April 29, 2026